OBRI is expanding its registry to include another set of inflammatory arthritis diseases called Spondyloarthritis or SpA for short. To date OBRI has focused on Rheumatoid Arthritis (RA), but this new expansion will allow us to study a broader range of inflammatory arthritic conditions. SpA includes Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Arthritis associated with Inflammatory Bowel Disease, Reactive Arthritis (ReA), Juvenile Idiopathic Arthritis that is Enthesitis-related (JIA-ERA) and Undifferentiated Spondyloarthritis (USpA).
Researchers will be looking at the different gene markers they believe to be associated with Spondyloarthritic diseases and determining the characteristics that result from each. They will check whether the original diagnosis made by the rheumatologist matches with current understandings of these diseases. Researchers will study disease activity, physical disability, quality of life, employment productivity, and the safety and effectiveness of treatments for SpA.
We’re very excited about this new expansion and look forward to keeping you up to date and sharing our results!